Drug Search Results
More Filters [+]

Mecasermin

Alternative Names: mecasermin, increlex
Latest Update: 2024-10-03
Latest Update Note: News Article

Product Description

Mecasermin (recombinant human insulin-like growth factor-I [IGF-I]) is approved in the US for the long-term treatment of growth failure in children with severe primary IGF-I deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH, and in the EU for the long-term treatment of growth failure in children and adolescents with severe primary IGF-I deficiency. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18481900/)

Mechanisms of Action: IGF Inhibitor

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Canada | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Taiwan | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Ipsen
Company Location: BOULOGNE BILLANCOURT CEDEX I0 92650
Company CEO: David Loew
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mecasermin

Countries in Clinic:

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Hypopituitarism

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2019-000843-29

P2

Active, not recruiting

Hypopituitarism

2020-11-30

2019-000844-81

P3

Active, not recruiting

Hypopituitarism

2019-06-15

Recent News Events